ReviewCurrent oncology reports2026
Radiotherapy for Meningiomas: Molecular, Imaging, and Therapeutic Advances.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose of review: Treatment of meningioma is rapidly evolving, as molecular classification, functional imaging, and radiotherapeutic techniques have undergone recent advances. The purpose of this review is to integrate these developments with clinical trial data to guide modern radiotherapy approaches. We specifically sought to address how new biological and imaging insights inform radiation planning, dose, and outcomes.Recent findings: Molecular classification provides prognostic insights beyond the classic WHO grading system. DOTATATE-PET has proven valuable for accurate delineation of tumor extent and biologically active regions, directly impacting radiotherapy planning. Recent clinical studies highlight the potential for improved local control with dose escalation and PET-guided planning. Ongoing clinical trials in the intact and salvage settings will provide further insight into the integration of imaging, biology, and radiotherapy.Summary: Radiotherapy for meningiomas is transitioning into a precision discipline, leveraging molecular and imaging biomarkers for individualized care. Integration of DOTATATE-PET, advanced radiation delivery techniques, and biologically guided dose escalation are redefining standards. Future research will test whether personalized, biomarker-driven radiotherapy can significantly improve outcomes in aggressive and recurrent meningiomas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.